NCT07357766

A Research Study to Compare Different Versions of Injectable CagriSema and Placebo in People With Excess Body Weight

A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or Obesity

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,400 (estimated)
• Sponsor: Novo Nordisk A/S · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is being done to find out how well a medicine called CagriSema helps people with overweight or obesity lose weight. CagriSema is still being tested in studies and is not yet available for doctors to prescribe. In this study the sponsor will compare two version of CagriSema injected by two different types of injection devices. Which treatment participants get is decided by chance using a computer program, so neither participants nor study staff will know which treatment is given. The study will last for about one year.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Cagrisema	Cagrisema (Cagrilintide and Semaglutide) will be administered subcutaneously using device 1 or device 2.
DRUG	Placebo CagriSema	Placebo matched to Cagrilintide and Placebo matched to Semaglutide will be administered subcutaneously using device 1 or device 2.

Timeline

• Start date: 2026-06-22
• Primary completion: 2027-11-29
• Completion: 2028-01-17
• First posted: 2026-01-22
• Last updated: 2026-02-25

Locations

116 sites across 14 countries: United States, Bulgaria, Denmark, Greece, Hungary, Malaysia, Poland, Portugal, Romania, Slovakia, South Africa, Switzerland, Taiwan, Thailand

Regulatory

• FDA-regulated drug study